Agreement adds two drug candidates to product pipeline consisting of (i) “EL-22”, a clinical stage engineered probiotic expressing myostatin, and (ii) “EL-32”, a preclinical engineered probiotic ...
Filed two patent applications for lead candidate EL-22, covering muscle loss in obese patients as a monotherapy and in combination with GLP-1 receptor agonists Elevai Biosciences patent portfolio now ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results